Mixing & matching IOLs not always to patient's advantage

Article

Using various types of IOLs in the same patient has been trumpeted as a way to achieve better vision correction than bilaterally implanting the same IOL. Yet, this concept of "mix and match" is not quite that simple.

Using various types of IOLs in the same patient has been trumpeted as a way to achieve better vision correction than bilaterally implanting the same IOL. Yet, this concept of “mix and match” is not quite that simple, said Rubens Belfort, MD, Vision Institute, Federal University, Sao Paulo, Brazil.

“Our experience tells us that such decisions depend on individual situations and patient expectations,” Dr Belfort said. “In each case, we must understand the patient and adopt his or her expectations.”

Dr Belfort compared and contrasted three studies. In the first, 40 patients received contralateral implantation with the apodized diffractive (ReSTOR; Alcon)/multifocal (ReZoom; AMO) lenses and were followed up at three months. In the second, 24 patients received bilateral implantation with the apodized diffractive IOL and were followed up at six months. The third study consisted of the label information for the apodized diffractive lens: 69 patients followed up at six months.

The studies had some similarities, such as inclusion criteria and methodology. They also had some differences: for example, the first study was randomized, while the other two were not.

Postoperative evaluation conducted by Dr Belfort included only those criteria that were the same for all three groups. In comparing the results of the three studies, Dr Belfort and his colleagues found that the best-corrected distance acuity was comparable across the three studies. “There were no advantages to mix and match, or mix and unmatch,” he said.The apodized diffractive lens pairing demonstrated improvements in near visual acuity compared with the patients who received the apodized diffractive/multifocal lenses.

“This is something we were not expecting,” Dr Belfort said. The same held true for intermediate visual acuity, as the apodized diffractive lens patients demonstrated improvement in intermediate vision compared with the apodized/multifocal lenses.

“We often hear how wonderful the mix-and-match concept is, but we didn't find that here,” Dr Belfort said. “The thing to remember is to put patients and their expectations first, in spite of all the technology and all the marketing.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.